The Benefits of Jakafi for Patients With PV

Jeanne M. Palmer, M.D.

Patients with PV tend to be very symptomatic, but Jakafi can help.

Jeanne M. Palmer, M.D., hematologist oncologist at the Mayo Clinic in Arizona discusses the benefit of Jakafi (ruxolitinib) for patients with polycythemia vera (PV) — a type of myeloproliferative neoplasm.

Patients with PV tend to be very symptomatic, and Jakafi provides good symptom control compared to some other PV treatments that have their own set of risks and side effects.

Related Content:

CURE TVMPN
‘Incredible’ That a One-Time Infusion of CAR-T Cell Therapy Induces Durable Responses in Acute Lymphoblastic Leukemia
Why It’s Important to Be a Well-Educated, Proactive Patient
Immunotherapy Could 'Provide A Whole New Realm' For Patients with Myeloma